We evaluated the EpCAM targeting ability of these aptamers in EpCAM-expressing CCA cells and demonstrated their utility as targeting ligands to develop EpCAM-targeted therapeutic nanovesicles. The gene discussed is EPCAM; the disease is cholangiocarcinoma.